For the year ending 2025-12-31, NKTR made $55,232,000 in revenue. -$164,076,000 in net income. Net profit margin of -297.07%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Total revenue | 55,232,000 | |||
| Cost of goods sold | 0 | |||
| Research and development (including 2,636 and 277 for the year ended december 31, 2025 and 2024, respectively, from a related party) | 117,330,000 | |||
| General and administrative | 68,673,000 | |||
| Restructuring and impairment | 9,331,000 | |||
| Gain on sale of the huntsville manufacturing facility | 0 | |||
| Total operating costs and expenses | 195,334,000 | |||
| Loss from operations | -140,102,000 | |||
| Non-cash interest expense on liabilities related to the sales of future royalties | 26,184,000 | |||
| Interest income | 10,438,000 | |||
| Other income (expense), net (including 1,110 and 0 for the year ended december 31, 2025 and 2024, respectively, from a related party) | 361,000 | |||
| Total non-operating income (expense), net | -15,385,000 | |||
| Loss before benefit for income taxes and equity method investment | -155,487,000 | |||
| Benefit for income taxes | -138,000 | |||
| Loss before equity method investment | -155,349,000 | |||
| Loss from equity method investment | -8,727,000 | |||
| Net loss | -164,076,000 | |||
| Basic EPS | -9.73 | |||
| Diluted EPS | -9.73 | |||
| Basic Average Shares | 16,870,930 | |||
| Diluted Average Shares | 16,870,930 | |||
NEKTAR THERAPEUTICS (NKTR)
NEKTAR THERAPEUTICS (NKTR)